Sickle cell strides

How Bioverativ will tap advances in HSC mobilization for sickle cell therapy BIVV003

Advances in hematopoietic stem cell mobilization procedures have enabled Bioverativ Inc. to bring its enhancer-targeted therapy, BIVV003, into the clinic for sickle cell disease. FDA accepted the IND for BIVV003 on Wednesday, and the company expects to start Phase I/II testing this year.

Under a 2014 deal

Read the full 465 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE